Literature DB >> 1873811

Characterization of multidrug resistance by fluorescent dyes.

D Kessel1, W T Beck, D Kukuruga, V Schulz.   

Abstract

Fluorimetric techniques were used to examine accumulation of fluorescent probes by the P388 murine leukemia and an anthracycline-resistant subline, P388/Adriamycin(ADR), which expresses the multidrug-resistant phenotype. P388 could be differentiated from P388/ADR on the basis of fluorescence intensity measurements using 3 classes of cationic dyes that are sensitive to membrane potential differences: rhodamine esters, cyanines, and styrylpyridinium dyes. But fluorescence intensity differences were also observed with potential-insensitive dyes: zwitterionic rhodamines and an acridine orange derivative. In all cases, fluorescence intensity differences were caused by impaired dye accumulation, and could be eliminated by treatment of P388/ADR cells with verapamil. Moreover, fluorescence signals from 2 anionic potential-sensitive dyes, merocyanine 540 and a bis-oxonol, were identical in P388 and P388/ADR. None of these dyes could be used to delineate CCRF-CEM, a lymphoblastic leukemia of human origin from the CEM/VM-1 subline that exhibits a markedly atypical drug resistance pattern not based on an enhanced outward transport. But accumulation of both neutral and cationic dyes was impaired in CEM/VLB100, a subline of CCRF-CEM expressing mdr. These studies show that many cationic and neutral fluorescent probes are substrates for the enhanced outward drug transport system associated with P388/ADR cells, and cannot be used to probe membrane-potential differences in cells expressing the mdr phenotype. With several dyes, differences in fluorescence intensity were sufficient so that flow cytometry could be used to delineate P388 from P388/ADR and CCRF-CEM from CEM-VLB100. The latter technique may be useful for identifying malignant cell populations expressing multidrug resistance in patients with neoplastic disease.

Entities:  

Mesh:

Substances:

Year:  1991        PMID: 1873811

Source DB:  PubMed          Journal:  Cancer Res        ISSN: 0008-5472            Impact factor:   12.701


  24 in total

1.  Direct assessment of P-glycoprotein efflux to determine tumor response to chemotherapy.

Authors:  Gauri Patwardhan; Vineet Gupta; Juowen Huang; Xin Gu; Yong-Yu Liu
Journal:  Biochem Pharmacol       Date:  2010-03-16       Impact factor: 5.858

2.  Phase I study of valspodar (PSC-833) with mitoxantrone and etoposide in refractory and relapsed pediatric acute leukemia: a report from the Children's Oncology Group.

Authors:  Maureen M O'Brien; Norman J Lacayo; Bert L Lum; Smita Kshirsagar; Steven Buck; Yaddanapudi Ravindranath; Mark Bernstein; Howard Weinstein; Myron N Chang; Robert J Arceci; Branimir I Sikic; Gary V Dahl
Journal:  Pediatr Blood Cancer       Date:  2010-05       Impact factor: 3.167

Review 3.  Cellular drug efflux and reversal therapy of cancer.

Authors:  P W Wigler
Journal:  J Bioenerg Biomembr       Date:  1996-06       Impact factor: 2.945

4.  Randomized use of cyclosporin A (CsA) to modulate P-glycoprotein in children with AML in remission: Pediatric Oncology Group Study 9421.

Authors:  David Becton; Gary V Dahl; Yaddanapudi Ravindranath; Myron N Chang; Fred G Behm; Susana C Raimondi; David R Head; Kimo C Stine; Norman J Lacayo; Branimir Ivan Sikic; Robert J Arceci; Howard Weinstein
Journal:  Blood       Date:  2005-10-27       Impact factor: 22.113

5.  A fluorometric screening assay for drug efflux transporter activity in the blood-brain barrier.

Authors:  Corbin J Bachmeier; Donald W Miller
Journal:  Pharm Res       Date:  2005-01       Impact factor: 4.200

6.  Accumulation of anthracenyl-amino acid topoisomerase I and II inhibitors in drug-sensitive and drug-resistant human ovarian cancer cell lines determined by high-performance liquid chromatography.

Authors:  J Cummings; I Meikle; J S Macpherson; J F Smyth
Journal:  Cancer Chemother Pharmacol       Date:  1995       Impact factor: 3.333

7.  Influence of sequential exposure to R-verapamil or B8509-035 on rhodamine 123 accumulation in human lymphoblastoid cell lines.

Authors:  E Roller; B Klumpp; J Krause; M Eichelbaum; K Schumacher
Journal:  Cancer Chemother Pharmacol       Date:  1993       Impact factor: 3.333

8.  New high-throughput screening assay to reveal similarities and differences in inhibitory sensitivities of multidrug ATP-binding cassette transporters.

Authors:  Marcin Kolaczkowski; Anna Kolaczkowska; Noboru Motohashi; Krystyna Michalak
Journal:  Antimicrob Agents Chemother       Date:  2009-02-02       Impact factor: 5.191

9.  Inhibition of cell-mediated cytolysis and P-glycoprotein function in natural killer cells by verapamil isomers and cyclosporine A analogs.

Authors:  W T Klimecki; C W Taylor; W S Dalton
Journal:  J Clin Immunol       Date:  1995-05       Impact factor: 8.317

Review 10.  P-glycoprotein expression and regulation. Age-related changes and potential effects on drug therapy.

Authors:  S Gupta
Journal:  Drugs Aging       Date:  1995-07       Impact factor: 3.923

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.